Merely 28 days after patient dosing, clinical data confirmed undetectable tumor cells in patient bone marrow, achieving outstanding early clinical efficacy.Subsequently, AstraZeneca completed the acquisition of EsoBiotec at USD 1 billion on March 17 of the same year, only two months following trial initiation.
The fast-track development from IIT launch to large-scale acquisition fully demonstrates the outstanding advantages of the IIT development path: shorter proof-of-concept cycle and lower R&D cost versus conventional IND routes for cell therapy projects.
CytoArt provides professional detection & bioanalytical support for global FIH IIT programs. Teams planning to launch investigator-initiated clinical trials are welcome to discuss customized supporting solutions with our team.